HIV Risk Reduction and Drug Abuse Treatment in Malaysia

Completed · Phase 2

Conditions studied: Opiate Dependence

In brief

A randomized clinical trial comparing drug abuse and HIV risk reduction counseling (DC-HIV) alone, DC-HIV combined with naltrexone maintenance, and DC-HIV combined with buprenorphine maintenance for the treatment of heroin addicts in Malaysia.

Key facts

Study ID

NCT00383045

Run by

Yale University

People needed

180

Starts

2003-04-01

Expected to finish

2007-08-01

Last updated by the study team

2020-03-31

Who can join

Age: 18 and older, up to 65. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Opioid dependence

You may not qualify if…

• Dependence on alcohol, benzodiazepines or sedatives
• Suicide or homicide risk
• Psychotic disorder or major depression
• Inability to read or understand the protocol or assessment questions
• Life-threatening or unstable medical problems
• Greater than 3 times normal liver enzymes (AST, GGT)

Where it is running

• Yale University School of Medicine — New Haven, Connecticut, United States
• Substance Abuse Research Center — Muar town, Johor, Malaysia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.